IL92167A - תכשיר המכיל אקטיבין ו/או אינהיבין - Google Patents
תכשיר המכיל אקטיבין ו/או אינהיביןInfo
- Publication number
- IL92167A IL92167A IL9216789A IL9216789A IL92167A IL 92167 A IL92167 A IL 92167A IL 9216789 A IL9216789 A IL 9216789A IL 9216789 A IL9216789 A IL 9216789A IL 92167 A IL92167 A IL 92167A
- Authority
- IL
- Israel
- Prior art keywords
- inhibin
- chain
- activin
- globin
- composition according
- Prior art date
Links
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 title claims abstract description 63
- 239000000893 inhibin Substances 0.000 title claims abstract description 57
- 108010059616 Activins Proteins 0.000 title claims abstract description 37
- 102000005606 Activins Human genes 0.000 title claims abstract description 37
- 239000000488 activin Substances 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 208000035475 disorder Diseases 0.000 claims abstract description 11
- 208000007056 sickle cell anemia Diseases 0.000 claims abstract description 11
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims abstract description 8
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 11
- 230000001605 fetal effect Effects 0.000 claims description 7
- 239000002243 precursor Substances 0.000 claims description 6
- 150000001413 amino acids Chemical group 0.000 claims description 5
- 208000005980 beta thalassemia Diseases 0.000 claims description 4
- 230000002441 reversible effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 101710107057 Inhibin beta chain Proteins 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 22
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 108091005886 Hemoglobin subunit gamma Proteins 0.000 abstract 1
- 102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 abstract 1
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 abstract 1
- 206010043391 Thalassaemia beta Diseases 0.000 abstract 1
- 102000002746 Inhibins Human genes 0.000 description 45
- 108010004250 Inhibins Proteins 0.000 description 45
- 210000003754 fetus Anatomy 0.000 description 14
- 108010044495 Fetal Hemoglobin Proteins 0.000 description 10
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 10
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 102000018146 globin Human genes 0.000 description 9
- 108060003196 globin Proteins 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 229940028334 follicle stimulating hormone Drugs 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 230000035935 pregnancy Effects 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 230000000925 erythroid effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010023082 activin A Proteins 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 238000000376 autoradiography Methods 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 210000004700 fetal blood Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000002903 Thalassemia Diseases 0.000 description 3
- 108010023079 activin B Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000001733 follicular fluid Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- -1 aspartyl residues Chemical group 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000008175 fetal development Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000036830 Normal foetus Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940099408 Oxidizing agent Drugs 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000002960 bfu-e Anatomy 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001717 carbocyclic compounds Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003013 erythroid precursor cell Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 208000020451 hereditary persistence of fetal hemoglobin Diseases 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/266,421 US4997815A (en) | 1988-11-01 | 1988-11-01 | Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL92167A0 IL92167A0 (en) | 1990-07-12 |
| IL92167A true IL92167A (he) | 1994-07-31 |
Family
ID=23014518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9216789A IL92167A (he) | 1988-11-01 | 1989-10-31 | תכשיר המכיל אקטיבין ו/או אינהיבין |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4997815A (he) |
| EP (2) | EP0617966A1 (he) |
| JP (1) | JPH02256622A (he) |
| AT (1) | ATE119396T1 (he) |
| CA (1) | CA2001897A1 (he) |
| DE (1) | DE68921546T2 (he) |
| IL (1) | IL92167A (he) |
| MA (1) | MA21667A1 (he) |
| PT (1) | PT92174B (he) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03173805A (ja) * | 1989-09-11 | 1991-07-29 | Ajinomoto Co Inc | 卵分割促進剤 |
| US5166190A (en) * | 1990-01-08 | 1992-11-24 | Genentech, Inc. | Method for increasing fertility in males |
| US5102868A (en) * | 1990-01-08 | 1992-04-07 | Genentech, Inc. | Method for inhibiting follicular maturation |
| US5942220A (en) * | 1990-03-16 | 1999-08-24 | Chiron Corporation | Inhibitor of cytokine activity and applications thereof |
| WO1991012334A1 (en) * | 1990-02-15 | 1991-08-22 | Cetus Corporation | Inhibitor of cytokine activity and applications thereof |
| WO1992004913A1 (en) * | 1990-09-13 | 1992-04-02 | Children's Hospital Medical Center Of Northern California | Method for increasing red blood cell production by treatment with activin or activin-related peptides |
| US7910624B1 (en) | 1995-03-03 | 2011-03-22 | The Trustees Of Boston University | Compositions for the treatment of blood disorders |
| USD354971S (en) | 1993-07-26 | 1995-01-31 | Mugnier Design | Eyeglasses |
| EP0664699A1 (en) * | 1993-08-13 | 1995-08-02 | Vitaphore Corporation | Hydrogel-based microsphere drug delivery systems |
| US5487895A (en) * | 1993-08-13 | 1996-01-30 | Vitaphore Corporation | Method for forming controlled release polymeric substrate |
| CA2174737C (en) * | 1993-10-29 | 2008-04-22 | Douglas V. Faller | Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents |
| US5700640A (en) * | 1994-09-16 | 1997-12-23 | Basf Aktiengesellschaft | Inducers of gamma globin gene expression and screening assays therefor |
| US5545616A (en) * | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
| US6011000A (en) * | 1995-03-03 | 2000-01-04 | Perrine; Susan P. | Compositions for the treatment of blood disorders |
| GB2306481A (en) * | 1995-10-21 | 1997-05-07 | Univ Manchester | Pharmaceutical comprising a stimulator of activin and/or inhibin |
| EP2298350A3 (en) | 1996-07-26 | 2011-06-08 | Susan P. Perrine | Composition comprising an inducing agent and an anti-viral agent for the treatment of viral disorders |
| AUPO638897A0 (en) * | 1997-04-23 | 1997-05-22 | Monash University | Modulation of cell growth and methods relating thereto |
| US6822267B1 (en) * | 1997-08-20 | 2004-11-23 | Advantest Corporation | Signal transmission circuit, CMOS semiconductor device, and circuit board |
| WO1999040883A2 (en) * | 1998-02-11 | 1999-08-19 | Faller Douglas V | Compositions and methods for the treatment of cystic fibrosis |
| AU2012203441B2 (en) * | 2002-05-17 | 2015-01-29 | Mount Sinai School Of Medicine Of New York University | Mesoderm and definitive endoderm cell populations |
| US20060003446A1 (en) * | 2002-05-17 | 2006-01-05 | Gordon Keller | Mesoderm and definitive endoderm cell populations |
| EP1543110A4 (en) * | 2002-05-17 | 2006-09-06 | Sinai School Medicine | POPULATION OF DEFINITIVE ENDODERMIC CELLS AND MESODERMAL |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7169801B2 (en) | 2003-03-17 | 2007-01-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20050137234A1 (en) * | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
| US20050159470A1 (en) * | 2003-12-19 | 2005-07-21 | Syrrx, Inc. | Histone deacetylase inhibitors |
| CA2575370A1 (en) * | 2004-08-10 | 2006-02-23 | Voyager Pharmaceutical Corporation | Methods for treating premature infants |
| EP1824831A2 (en) * | 2004-12-16 | 2007-08-29 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| JP2008540574A (ja) * | 2005-05-11 | 2008-11-20 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| JP2009501236A (ja) * | 2005-07-14 | 2009-01-15 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| JP2009525955A (ja) * | 2006-01-13 | 2009-07-16 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| US8874380B2 (en) | 2010-12-09 | 2014-10-28 | Rutgers, The State University Of New Jersey | Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs |
| WO2010105112A1 (en) * | 2009-03-11 | 2010-09-16 | Hemaquest Pharmaceuticals, Inc. | Detection of short-chain fatty acids in biological samples |
| US20110086869A1 (en) | 2009-09-24 | 2011-04-14 | The Trustees Of Boston University | Methods for treating viral disorders |
| CN102802412A (zh) | 2009-12-08 | 2012-11-28 | 海玛奎斯特医药公司 | 用于治疗红细胞病症的方法及低剂量方案 |
| WO2011113013A2 (en) | 2010-03-11 | 2011-09-15 | Hemaquest Pharmaceuticals, Inc. | Methods and compositions for treating viral or virally-induced conditions |
| US10039813B2 (en) | 2012-02-07 | 2018-08-07 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| US9724396B2 (en) | 2013-03-15 | 2017-08-08 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
| WO2016064815A1 (en) * | 2014-10-20 | 2016-04-28 | Massachusetts Institute Of Technology | Functional ghrelin receptor antagonism during pregnancy to prevent stress-associated mental illness in offspring and mothers |
| WO2016138099A1 (en) | 2015-02-24 | 2016-09-01 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
| EP3484489B1 (en) | 2016-07-15 | 2025-06-18 | Viracta Subsidiary, Inc. | Hdac inhibitors for use with nk cell based therapies |
| CA3142142A1 (en) | 2019-05-31 | 2020-12-03 | Viracta Subsidiary, Inc. | Methods of treating virally associated cancers with histone deacetylase inhibitors |
| CA3236051A1 (en) | 2021-10-19 | 2023-04-27 | Akirabio, Inc. | Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0730114B2 (ja) * | 1985-04-03 | 1995-04-05 | 正雄 五十嵐 | インヒビン |
| JPH0637520B2 (ja) * | 1985-07-03 | 1994-05-18 | 味の素株式会社 | ポリペプチド |
| US4740587A (en) * | 1985-07-18 | 1988-04-26 | The Salk Institute For Biological Studies | Inhibin and method of purifying same |
| NZ231899A (en) * | 1985-10-03 | 1991-07-26 | Genentech Inc | Human or porcine inhibin peptide compositions and dna encoding them |
| NZ217821A (en) * | 1985-10-10 | 1989-07-27 | Biotech Australia Pty Ltd | Oral delivery system; complex of active agent and vitamin b12 or analogue thereof |
| US4822821A (en) * | 1986-10-10 | 1989-04-18 | Children's Hospital Medical Center Of Northern California | Method for augmenting fetal hemoglobin |
| EP0299050B1 (en) * | 1987-01-29 | 1995-03-22 | Biotechnology Australia Pty. Ltd. | Isolation of single chain proteins with fsh suppressing activity from follicular fluid |
| GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| US5032507A (en) * | 1987-11-13 | 1991-07-16 | The Salk Institute For Biological Studies | Potentiation of erythropoiesis |
-
1988
- 1988-11-01 US US07/266,421 patent/US4997815A/en not_active Expired - Fee Related
-
1989
- 1989-10-31 IL IL9216789A patent/IL92167A/he not_active IP Right Cessation
- 1989-10-31 CA CA002001897A patent/CA2001897A1/en not_active Abandoned
- 1989-10-31 MA MA21919A patent/MA21667A1/fr unknown
- 1989-11-01 JP JP1286002A patent/JPH02256622A/ja active Pending
- 1989-11-01 EP EP94200748A patent/EP0617966A1/en not_active Withdrawn
- 1989-11-01 EP EP89311297A patent/EP0367590B1/en not_active Expired - Lifetime
- 1989-11-01 AT AT89311297T patent/ATE119396T1/de active
- 1989-11-01 DE DE68921546T patent/DE68921546T2/de not_active Expired - Fee Related
- 1989-11-02 PT PT92174A patent/PT92174B/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PT92174A (pt) | 1990-05-31 |
| PT92174B (pt) | 1995-09-12 |
| EP0617966A1 (en) | 1994-10-05 |
| ATE119396T1 (de) | 1995-03-15 |
| IL92167A0 (en) | 1990-07-12 |
| JPH02256622A (ja) | 1990-10-17 |
| EP0367590B1 (en) | 1995-03-08 |
| MA21667A1 (fr) | 1990-07-01 |
| US4997815A (en) | 1991-03-05 |
| EP0367590A3 (en) | 1992-01-02 |
| DE68921546D1 (de) | 1995-04-13 |
| CA2001897A1 (en) | 1990-05-01 |
| DE68921546T2 (de) | 1995-07-06 |
| EP0367590A2 (en) | 1990-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4997815A (en) | Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin | |
| US5216004A (en) | Method for preventing malaria | |
| EP0548276A4 (en) | Method for increasing red blood cell production by treatment with activin or activin-related peptides | |
| US5646113A (en) | Treatment of partial growth hormone insensitivity syndrome | |
| US5126324A (en) | Method of enhancing growth in patients using combination therapy | |
| EP0602050B1 (en) | Method of stimulating immune response | |
| US5597802A (en) | Method of formulating IGF-I with growth hormone | |
| US4699897A (en) | Biologically active peptides structurally related to regions within growth hormones | |
| HK1007954B (en) | The combination of growth hormone and insulin-like growth factor-i enhances growth | |
| CA2185998C (en) | The combination of growth hormone and insulin-like growth factor, for treating congestive heart failure | |
| AU2003229222B2 (en) | GRF analog compositions and their use | |
| US5824642A (en) | Treatment of partial growth hormone insensitivity syndrome | |
| US10695402B2 (en) | Erythropoietin for gastrointestinal dysfunction | |
| JPH08502969A (ja) | 肥満の予防または治療方法 | |
| US6207640B1 (en) | Treatment of partial growth hormone insensitivity syndrome | |
| Cotes | Erythropoietin: the developing story | |
| US5317012A (en) | Human growth hormone induced improvement in depressed T4/T8 ratio | |
| WO1999049894A1 (en) | Antagonists to growth arrest specific gene 6 to treat insulin-resistant disorders | |
| Baumann | Molecular heterogeneity of circulating growth hormone in acromegaly | |
| MXPA98009140A (en) | Treatment of the partial insensitivity syndrome to the growth hormone | |
| JPH03505088A (ja) | ホルモン類の作用 | |
| MXPA96004802A (en) | Treatment of cardiac failure congest | |
| HK1062395A (en) | Treatment of partial growth hormone insensitivity syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RH | Patent void |